Abstract

 Obesity-associated type 2 diabetes (T2D) arises from chronic positive energy balance, adipose tissue dysfunction, 
low-grade inflammation, and insulin resistance. Converting energy-storing white adipose tissue into 
thermogenically active beige/brown–like adipocytes “browning”offers a compelling means to increase energy 
expenditure and improve glucose homeostasis by elevating uncoupling protein-1 (UCP1)–dependent respiration 
and mitochondrial biogenesis. Yet pharmacologic agents that induce browning often suffer from poor 
bioavailability, off-target toxicity, and inadequate delivery to adipose depots. Nanotechnology enables precise 
spatiotemporal control over therapeutic cargoes, including small molecules, peptides, and nucleic acids, while 
exploiting tissue-specific targeting, controlled release, and stimuli-responsiveness. Here, we review design 
principles for adipose-directed nanomedicines that activate thermogenic pathways; emerging nucleic acid 
strategies that reprogram adipocyte fate; small-molecule and nutraceutical payloads formulated for enhanced 
efficacy; and imaging modalities and biomarkers that quantify browning in vivo. We also consider safety, 
manufacturing, and regulatory issues that must be overcome for translation, and propose pragmatic clinical trial 
frameworks tailored to metabolic endpoints. By integrating materials science with adipose biology, 
nanotechnology can turn browning from a laboratory phenomenon into a clinically actionable modality for T2D, 
potentially complementing lifestyle interventions and incretin-based therapies while minimizing cardiovascular 
and sympathetic side effects.